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The fountain of youth, the elixir of life, the 
Philosopher’s stone, or an analogous mythical object to 
remedy the scourges of aging, has been sought after 
throughout the history of humankind, up to the present 
day. In modern times, inventing a drug that prevents the 
aging-linked decline in organ function, expands the 
years of life spent in good health, or even increases 
lifespan promises fame and fortune for the discoverer. 
Vitamins, anti-oxidants, resveratrol and other alleged 
sirtuin activators, caloric restriction, nicotinamide 
adenine dinucleotide (NAD+) and its biosynthetic pre-
cursors, young blood and growth and differentiation 
factor 11 (GDF 11), senolytics, rapamycin and rapalogs, 
metformin as well as numerous other compounds and 
treatments all were (or still are) considered as the magic 
bullet for “anti-aging” effects in the last couple of years 
[1]. However, for most, if not all of them, preclinical 
results in animal models were difficult to translate to 
humans, unexpected adverse effects in animals or 
humans were reported, and/or clinical trials showing 
any efficacy in healthy young and old individuals are 
still elusive [1]. Importantly, aging per se is not 
recognized as a disease, and so-called “anti-aging” 
effects are often difficult to disentangle from disease 
prevention. For example, it is not entirely clear whether  
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the beneficial outcome of caloric restriction in non-
human primates is due to a reduction of numerous 
diseases observed in control-fed primates (whatever 
control levels mean in a laboratory context for these 
animals), or if true “anti-aging” effects were achieved 
[2]. In stark contrast to the currently proposed putative 
“anti-aging” drugs, a combination of various lifestyle-
based approaches clearly achieves the best epi-
demiological risk profile for healthy aging, with 
minimal or no adverse effects (Figure 1). Moreover, 
some of these approaches, for example exercise 
training, are not only highly efficient in preventing 
certain chronic diseases, but also in the treatment of 
numerous pathologies [3]. However, the molecular basis 
of the health beneficial effect of exercise remains 
largely enigmatic. For example, novel protective 
pathways elicited by exercise training, e.g. via the effect 
of the central regulator peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α) on mito-
chondrial calcium handling, endoplasmic reticulum 
stress, tubular aggregates and cell death in old muscle, 
highlight the complexity of the training response and 
some of the consequences for muscle aging in sedentary 
or active individuals [4]. In fact, exercise remains the 
only currently available intervention to mitigate, and   
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Figure 1. How to age in a healthy manner. Examples of behavioral and lifestyle aspects that reduce the risk for developing chronic 
diseases, help in mitigating pathological events, and decrease morbidity and mortality, thus collectively contributing to healthy aging. 
At the moment, it is unclear how a single or even multiple pharmacological agents can elicit a similar broad and complex response. 
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even reverse the age-related decline in muscle mass and 
function, known as sarcopenia. As in other diseases, the 
usage of anabolic steroids and growth hormones for the 
treatment of sarcopenia has largely failed, due to lack of 
efficacy in non-replacement therapies and unacceptable 
adverse effects. Moreover, since the molecular 
underpinnings of the etiology and progression of 
sarcopenia are unknown, a more targeted pharma-
cological intervention remains elusive. In recent years, 
the controversial concept of designing and deploying 
so-called exercise “mimetics”, pharmacological com-
pounds that induce effects similar to those observed 
after bona fide training, has gained traction to 
circumvent the inherent problem of insufficient 
mechanistic knowledge [5]. The ongoing broad 
discussion about exercise “mimetics” to a large extent 
mirrors that about potential “anti-aging” drugs. In both 
fields, it is difficult to reconcile how pharmacological 
modulation of specific pathways would address the 
complex, pleiotropic, multi-faceted and systemic 
plasticity observed in exercise adaptation and the aging 
process, respectively [6]. Intriguingly, besides the 
overlap in some compounds proposed to work as 
exercise, caloric restriction “mimetics” and “anti-aging” 
drugs, such as resveratrol [5], other compounds exert 
seemingly diametrically opposite effects. For example, 
the anti-anabolism elicited by putative “anti-aging” 
drugs such as rapamycin, or the inhibition of insulin and 
insulin-like growth factor signaling in experimental 
models, are opposed to the anabolic action that is 
desired in exercise in general, but most particularly in 
resistance training. Indeed, the activity of the 
mammalian target of rapamycin complex 1 (mTORC1) 
is elevated in resistance-trained muscle, and rapamycin 
efficiently blocks muscle hypertrophy in certain 
paradigms. Similarly, metformin and resveratrol 
impaired beneficial adaptations to endurance exercise in 
some trials, even though mechanistically, these two 
compounds could have been expected to initiate 
endurance training-like effects [1, 5]. These obser-
vations emphasize the complexity of cellular and 
organismal adaptation to exercise and aging that 
impedes the development of pharmacological mono-
therapies. Thus, the next years will not only reveal 
whether promising preclinical results with such 
compounds will stand the test of time in human trials, 
but also indicate the compatibility with other inter-
ventions and treatments. However, as long as data about 
clinical efficacy and safety of exercise “mimetics” and 
“anti-aging” drugs are missing (and probably even 
beyond that), lifestyle-based interventions remain the 
mainstay approach to minimize the risk for diseases, 
reduce morbidity and mortality and most importantly, 
improve healthspan in aging [7]. The old adage “use it 
or lose it” should thus serve as a reminder that regular 
physical activity is directly and strongly linked to health 
in the young and the elderly [8]. 
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